Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Condition: Type 2 Diabetes Mellitus
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Intervention: Dapagliflozin 5 mg; Placebo tablet
Intervention description: Dapagliflozin, a blood glucose lowering drug. Oral dose; Placebo tablet. Oral dose
Intervention MeSH terms: Dapagliflozin
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 266.0
Sex: All
Minimum age: 20 Years
Maximum age: 130 Years
Healthy volunteers: No
Keywords: Japanese patients with type 2 diabetes with inadequate glycemic control on insulin

Summary:

      Japanese male and female patients with Type 2 Diabetes and aged ≥ 20 years old, with
      inadequate glycemic control on insulin defined as Haemoglobin A1c ≥ 7.2% and < 11% will be
      enrolled into the wash-out phase or directly into the lead-in phase depending on whether the
      patient has been receiving an Oral antidiabetic drug (including Glucagon-Like Peptide-1
      agonists and excluding Thiazolidinedions) other than a Dipeptidyl Peptidase-4 inhibitor as
      part of the baseline treatment. Additional treatment with a concomitant Dipeptidyl
      Peptidase-4 inhibitor is allowed. And around 180 eligible patients in total will be
      randomized into the study with a 2:1 randomization scheme (i.e.120 patients into the
      dapagliflozin treatment group and 60 patients into the placebo treatment group. All subjects
      who completed a 16 weeks double-blind treatment period will shift to a 36 weeks open
      extension treatment period.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Diagnosis of Type 2 Diabetes according the criteria specified by the Japan Diabetes
             Society

          -  Japanese Men or women age ≥ 20 years at time of consenting.

          -  Stable (unless adjustment is required based on Fasting Plasma Glucose values) dose
             insulin* mono-therapy with the mean insulin [up to two types of insulin within
             authorized indication in Japan] dose of ≥ 0.2 IU/kg/day AND ≥ 15 IU/body/day over the
             past 8 weeks prior to enrolment.

          -  HbA1c ≥ 7.2% and < 11% from the blood samples collected at Visit 1 (enrolment) and
             Visit 3, observed from the central laboratory

        Exclusion Criteria:

          -  Diagnosis of Type 1 diabetes mellitus, known diagnosis of Maturity Onset Diabetes of
             the Young, secondary diabetes mellitus or diabetes insipidus

          -  History of diabetic ketoacidosis.

          -  Thyroid-stimulating hormone and free T4 values outside normal range, observed from the
             central laboratory; an abnormal Thyroid-stimulating hormone value needs to be followed
             up with a free T4 test. Patients with abnormal free T4 values will be excluded at
             Visit 1

          -  Fasting Plasma Glucose >240 mg/dL (twice in a row) despite the permitted dose
             adjustment of insulin therapy during washout period and lead-in period.

          -  Recent cardiovascular events in a patient.

          -  eGFR <45 mL/min/1.73 m2 at Visit 3, observed from the central laboratory.

          -  History of unstable or rapidly progressing renal disease.

          -  History of unexplained microscopic or gross hematuria, or microscopic hematuria at
             Visit 1, confirmed by a follow-up sample at next scheduled visit, where according to
             the investigator a satisfactory evaluation of hematuria has not been conducted.

          -  Severe hepatic insufficiency and/or significant abnormal liver function defined as
             aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine
             aminotransferase (ALT) >3x ULN, observed from the central laboratory at Visit 1.

          -  Total bilirubin >2.0 mg/dL (34.2 μmol/L), observed from the central laboratory at
             Visit 1.

          -  Positive serologic evidence of current infectious liver disease including Hepatitis A
             viral antibody IgM, Hepatitis B surface antigen and Hepatitis C virus antibody,
             observed from the central laboratory.

          -  Haemoglobin <10 g/dL (<100 g/L) or 6.2 mmol/L for men; haemoglobin <9.0 g/dL (<90 g/L)
             or 5.9 mmol/L for women, observed from the central laboratory at Visit 1.

          -  History of chronic haemolytic anaemia or haemoglobinopathies (for example, sickle cell
             anaemia, thalassemia, sideroblastic anaemia). Mild haemolysis due to artificial heart
             valves or due to sickle cell trait is not an exclusion criterion except when
             haemoglobin levels are too low (as defined in haemoglobin criteria above).

          -  History of malignancy within the last 5 years prior to enrolment, excluding successful
             treatment of basal or squamous cell skin cancer.